MEDICINOVA COMPLETES ENROLLMENT FOR ASTHMA STUDY

MediciNova has announced the completion of patient enrollment in a Phase II clinical study with MN-001 for the treatment of asthma. MN-001, which is orally administered, is a leukotriene receptor antagonist.

The clinical study, which has been ongoing for six months, has enrolled 147 patients with mild to moderate asthma. Patients will complete treatment by the end of October. Results from this Phase II study will be analyzed and data will be available during the fourth quarter of the year. The placebo-controlled study is designed to evaluate trends in the effectiveness of three different dosing regimens of MN-001 on improvement of respiratory function by various measures, including increases in forced expiratory volume, reduction in the response to methacoline challenge, and the duration of these improvements following dosing and improvement after four weeks of treatment compared with that observed on the first day of treatment. The safety and tolerability of MN-001 will also be evaluated.